Trial Profile
A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary) ; Dacarbazine; Temozolomide
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 05 Oct 2021 This trial has completed in Spain, as per European Clinical Trials Database record
- 07 Jan 2013 Results published in the Journal of Clinical Oncology.
- 29 Sep 2009 Planned end date changed from Dec 2010 to Dec 2011 as reported by ClinicalTrials.gov.